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Abstract
Early recognition and rapid initiation of effective treatment is a prerequisite for successful management of children with invasive fungal
infections. The increasing diversity of fungal pathogens in high-risk patients, the differences in the antifungal spectra of available agents
and the increasing rates of resistance call for identiﬁcation of the infecting isolate at the species level and for information on drug
resistance, in order to provide state-of-the-art patient care. Microscopy and culture of appropriate specimens remain the reference
standard for mycological diagnosis, despite difﬁculties in obtaining appropriate and/or sufﬁcient specimens, long durations of culture and
false-negative results. Modern imaging studies and detection of circulating fungal cell wall components and DNA in blood and other
body ﬂuids or in affected tissues may improve the laboratory diagnosis of invasive mycoses.
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Introduction
Early mycological diagnosis and antifungal therapy are crucial
for surviving invasive fungal infections (IFIs) in patients of all
ages. In a prospective study in adult patients with pulmonary
aspergillosis, timely implementation of antifungal therapy
based on positive bronchoscopy and high-resolution com-
puted tomography (CT) scan results had a signiﬁcant impact
on survival. Starting antimycotics within the ﬁrst 10 days after
the onset of pneumonia resulted in a fatality rate of 41%, as
opposed to 90% when treatment was begun later (p <0.01)
[1]. Early initiation of amphotericin was also associated with
improved outcome in adult patients with sinopulmonary
mucormycosis [2]. Similarly, in patients with candidaemia, a
delay in antifungal treatment of greater than 12 h after clinical
suspicion (i. e. obtaining a blood culture) was associated with
a 20% increase in mortality [3], with further signiﬁcant
increases on each of the following 3 days [4]. However,
detection of IFIs by conventional culture and microscopic
methods remains time-consuming and insensitive. Berenguer
et al. [5] found that blood cultures were frequently negative
in patients who had autopsy-proven deeply invasive candidia-
sis. Difﬁculty in collecting appropriate tissue specimens for
culture or histology, particularly in neutropenic and throm-
bocytopenic patients, represents a further limitation in the
conventional diagnosis of IFI.
Clinical Evaluation
A diagnosis of IFI in an immunocompromised child begins
with an assessment of risk. Such an assessment includes
evaluation of the probability that a patient’s clinical manifes-
tations are caused by an IFI. Factors such as primary
neoplastic disease, quantitative and qualitative defects in
neutrophils, monocytes, T-cells, B-cells, antibodies and
cytokines, mucosal integrity and immunosuppressive treat-
ment are critical in this evaluation of risk. A careful history
and meticulous physical examination complement bedside
assessment, while also providing a guide to rational
selection of diagnostic imaging modalities and laboratory
studies.
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Diagnostic Imaging Studies
Invasive aspergillosis (IA) and other mould infections
Whereas conventional chest radiographs lack sensitivity in
neutropenic patients, serial high-resolution CT in neutropenic
adults has been shown to positively impact on the early
diagnosis and outcome of invasive pulmonary aspergillosis
(IPA) [6]. The characteristic ‘halo’ sign is an early stage of the
disease; it is indicative of perifocal haemorrhage, coagulative
necrosis and oedema surrounding a dense fungal nodule [7,8],
and is associated with improved prognosis [9]. Pulmonary nod-
ules with a ‘halo’ sign have also been found in non-Aspergillus
fungal pneumonia caused by Fusarium spp., Scedosporium
spp. or Zygomycetes, in bacterial pneumonia caused by
Pseudomonas aeruginosa, and in neoplastic and non-infectious
inﬂammatory diseases [10,11], rendering this radiographic
feature less speciﬁc for IPA.
There is growing recognition that CT features of pulmo-
nary lesions characteristic for adult IPA are less frequent in
children [12,13]. Further signs, such as central cavitation of
pulmonary lesions and the ‘air-crescent’ sign, appearing later
in the course of IPA in approximately 40% in adult series,
were not or less commonly observed in children [12,14].
Instead, focal bronchopneumonia is more frequently identi-
ﬁed in paediatric patients with IPA.
Routine serial CT imaging in children carries a considerable
risk of radiation exposure that is proportionally greater than
that of adults [15] and may lead to additional infections follow-
ing environmental exposures during patient transportation and
contact.
Chronic disseminated or hepatosplenic candidiasis
Whereas open liver biopsy with mycological and histological
evaluations remains the reference standard diagnostic pro-
cedure for hepatosplenic candidiasis, magnetic resonance
imaging (MRI) has the highest diagnostic value, detecting hy-
perintense fungal lesions on T2-weighted images with a sen-
sitivity of 100% and a speciﬁcity of 96% [16]. However,
MRI requires sedation in small children, and may often be
unavailable or too expensive as compared with other meth-
ods. Biphasic liver CT scan as an alternative shows lesions
with typical central contrast enhancement and a peripheral
double ring in the arterial phase in adults [17]. As radiation
exposure should be considered, particularly in children,
high-resolution ultrasonography is a reasonable initial alter-
native for screening, despite a lower level of sensitivity than
those of CT and MRI [18–21]. As the lesions of dissemi-
nated candidiasis are more readily observed when associ-
ated with inﬂammation, imaging modalities are best
performed in oncology patients and haematopoietic stem
cell transplant recipients after recovery from neutropenia.
Conventional Laboratory Methods for
Diagnosis of IFIs
Microscopy by direct examination, wet mount, cytology and
histology are practical and relatively inexpensive methods for
detection of IFIs. Culture techniques, including for blood cul-
tures continue to improve, but nonetheless remain limited
for the early detection of mycoses.
Some studies suggest that approximately 60–80% of candi-
daemia patients can be diagnosed with contemporary blood
culture systems [22,23], albeit with a delay that signiﬁcantly
affects survival [3,4]. Among moulds, Fusarium spp., Scedospo-
rium spp. and Aspergillus terreus may cause fungaemia that is
detectable by blood culture. Other moulds are less likely to
be detectable as a cause of fungaemia [24].
Detection of Fungal Cell Wall Markers
Carbohydrate molecules of the fungal cell wall have been
intensively studied in the last two decades as markers for IFI.
Glucans are almost universal fungal cell wall components,
whereas mannans are mainly found in yeasts, and galacto-
mannan (GM) is rather speciﬁc for Aspergillus spp. [25].
On the basis of their performance in adults, two standard-
ized methods for detection of fungal biomarkers in serum
have been approved by the US Food and Drug Administra-
tion and have been included in the consensus criteria for
diagnosis of IFI [26]: the GM antigen enzyme immunoassay
(EIA) (Platelia Aspergillus; BioRad, Marnes-la-Coquette,
France) and two assays detecting (1 ﬁ 3)-b-D-glucan (BDG)
(Fungitell; Associates of Cape Cod, Falmouth, MA, USA; Fun-
gitec G; Seikagaku Corp., Tokyo, Japan).
Galactomannan (GM)
GM is a heteropolysaccharide found within the cell wall of
Aspergillus spp. During hyphal growth and cell wall turnover,
GM is released into the extracellular ﬂuid. The GM antigen
ELISA allows for the detection of Aspergillus spp. in serum
[27]. A recent meta-analysis revealed various sensitivity
rates, from 30% to 100%, and similarly wide-ranging speciﬁci-
ties, from 38% to 98% [28]. By means of this method, GM
can also be detected in urine, bronchoalveolar lavage (BAL)
ﬂuid, cerebrospinal ﬂuid (CSF) and other specimens [29,30].
Relative to adults, there is also a comparably wide range
of sensitivity of GM EIA applied to serum samples of children
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with IA. Hayden et al. studied the expression of GM antigen
by EIA in 56 paediatric oncology patients (aged 3 months to
18 years), of whom 17 had European Organization for
Research and Treatment of Cancer-deﬁned proven or proba-
ble IA. At least one serum sample was positive for 11 of 17
paediatric oncology patients (65.7% sensitivity, 95% CI 38.3–
85.7) with IA. Among the seven evaluable GM-positive
patients with IA, the GM EIA produced a positive result
before clinical or radiographic evidence of infection in six
cases, with a lead time to diagnosis ranging from 1 day to
34 days (median: 10 days) [31]. On the other hand, a rela-
tively low sensitivity was reported in paediatric cancer
patients by Herbrecht et al. [32], as well as recently by
Castagnola et al. [33]. Moreover, non-neutropenic children
with chronic granulomatous disease or Job’s syndrome
(Walsh et al., 40th IDSA meeting, 2002, Abstract 345) also
had low expression of GM, possibly because of more local-
ized and less angio-invasive disease as well as the unique
immunological factors mentioned previously [34].
Several factors limiting the speciﬁcity of the GM EIA also
have been identiﬁed. Whereas immunoreactivity with other
organisms, such Penicillium spp., Paecilomyces spp., Blastomyces
dermatitidis, Nigrospora and Trichothecium is uncommon,
false-positive results can be caused more frequently by
contaminating GM in certain b-lactam antibiotics, particularly
piperacillin–tazobactam [35,36] and amoxycillin with or with-
out clavulanate [37], dietary GM in pasta, cereals and formula
milk, and immunoreactivity of the EB-A2 antibody used in
the method involving lipoteichoic acids of Biﬁdobacterium
spp., which are commonly found in the infant gut microﬂora
[38]. In contrast, two paediatric studies, analysing twice-
weekly screening periods in 119 and 64 high-risk patients,
respectively, revealed favourable speciﬁcity of the GM EIA,
particularly when patients receiving piperacillin–tazobactam
were excluded from the analysis [33,39].
Another recent paediatric study also suggests utility of the
GM EIA when applied to BAL ﬂuid of patients with sus-
pected PA [40]. This observation of the diagnostic utility of
GM in BAL ﬂuid is compatible with what has been observed
in adults and in laboratory animals with IPA [41,42].
(1 ﬁ 3)-B-D-glucan (BDG)
BDG is present in the cell wall of most pathogenic fungi.
BDG detection is not species-speciﬁc or genus-speciﬁc, but
is sensitive for a broad range of fungal pathogens, including
Aspergillus spp., other moulds, Candida spp. and Pneumocystis.
As the Mucorales (Mucor spp., Rhizopus spp. and Lictheimia
(Absidia) spp.), Cryptococcus neoformans and Blastomyces der-
matitidis contain relatively small amounts of cell wall BDG,
infections caused by these organisms may not be reliably
detected by BDG assays. In the two available assays, BDG
acts as a speciﬁc trigger of the coagulation cascade occurring
in the endolymph of the horseshoe crab (Limulus polyphemus
or Tachypleus tridentatus) through activation of factor G (after
removal of the endotoxin-sensitive factor C) [43–45].
In clinical studies examining the diagnostic value of
the available BDG assays in adult patients, sensitivities of
55–100%, speciﬁcities of 71–93%, positive predictive values
(PPVs) of 40–89% and negative predictive values (NPVs)
of 73–100% have been reported, with the use of various
cut-off values for positivity ranging from 6 to 120 pg/mL
[44,46–53].
For the Fungitec assay (developed in Japan), which utilizes
the endolymph of T. tridentatus, a cut-off level of 20 pg/mL
was deﬁned for plasma samples. An early analysis of 202 feb-
rile episodes, including 41 episodes of IFI, revealed 90% sen-
sitivity and 100% speciﬁcity for this test [44]. Later, a
sensitivity of 67% and a speciﬁcity of 84% were observed in
33 patients with IA [46]. Recently, this BDG assay was pro-
spectively re-evaluated with twice-weekly screening during
190 neutropenic episodes in 95 patients treated for acute
leukaemia with a high incidence of IFI (nine proven, 23 prob-
able and 30 possible cases). If two consecutive positive
results were considered to be diagnostic, a threshold of
7 pg/mL resulted in the best diagnostic performance, with
63% sensitivity, 96% speciﬁcity, 79% PPV and 91% NPV in
patients with proven or probable IFI [53].
The Fungitell (formerly Glucatell) assay (USA) utilizes the
endolymph of L. polyphemus. A 60 pg/mL cut-off value was
recommended, on the basis of a study in serum samples of
30 adult patients with candidaemia and 30 healthy controls.
The false-positive rate was 4.3%. The Fungitec G
assay—analysed in parallel—was found to be 2.5 times less
reactive than the Glucatell assay, but performed equally
when the respective lower threshold was used [47].
In a multicentre clinical evaluation with 60 and 80 pg/mL
cut-off values, the Fungitell assay detected proven and
probable IA in eight of ten patients, proven candidiasis
(n = 107) in 81.3% and 77.6%, and fusariosis in all three
patients. Lower overall sensitivities (69.9% and 64.4%,
with corresponding speciﬁcities of 87.1% and 92.4%)
were observed among all IFI cases, because, expectedly,
only three of 12 patients with Cryptococcus infection and
none of the three patients with zygomycoses were BDG-
positive. Among patients on ﬂuconazole prophylaxis, a
slightly, but non-signiﬁcantly, lower sensitivity was observed
than in subjects who had proven IFI not receiving antifungal
therapy [48].
It is worth noting possible causes of false-positive BDG
assays results. Small amounts of glucans affecting test
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speciﬁcity have been found in cellulose used in surgical gauze,
haemodialysis membranes and for ﬁltration of blood prod-
ucts such as immunoglobulin, albumin and coagulation factors
[25]. A case report described false-positive BDG results in
six consecutive patients treated with amoxycillin–clavulanic
acid [54]; however, in vitro studies suggest that serum BDG
levels can be only minimally inﬂuenced by infusion of most
contaminated antibiotics [55].
Comparative studies between GM and BDG
A BDG assay (Glucatell) and the GM EIA (Platelia Aspergillus)
were compared in 40 neutropenic adults with the use of a
twice-weekly screening schedule for diagnosis of IA. In order
to improve the speciﬁcity of the tests, rather high thresholds
(120 pg/mL for the BDG assay and 1.5 for the GM EIA) were
chosen. Five proven, three probable and three possible IA
cases were diagnosed. Among this low number of cases, the
sensitivity, speciﬁcity, PPV and NPV were identical for both
the BDG and the GM assays (87.5%, 89.6%, 70% and 96.3%,
respectively), with a false-positive rate of 10.3% each, albeit
represented by different patients. The sensitivities of both
tests were 100% in patients with proven IA and 66% in
patients with probable IA. The use of both assays in combina-
tion further improved the speciﬁcity and PPV to 100%, with-
out affecting the sensitivity and NPV [49].
Another comparative study conﬁrmed an NPV of 97.8%
for the BDG assay, suggesting particular utility for excluding
IFIs in high-risk patients. Almost all (31/32) study patients
with IA who had positive GM assay results were also posi-
tive in the BDG assay, whereas the BDG results of GM-neg-
ative patients were repeatedly positive. In contrast, the
speciﬁcity was only 77%, owing to a considerable number of
false-positive results, mainly in patients with (mostly Gram-
positive) bacteraemia [50]. Whereas, in this study, 56% (14/
25) of bacteraemic patients were BDG-positive, a recent
study found elevated BDG values in only two of 93 patients
with documented bacteraemia without concomitant IFI;
‘false’-positive BDG ﬁndings occurred only in patients with
fungal colonization and/or mucositis who received empirical
antifungal treatment, suggesting an occult fungal cause [53].
A recent prospective trial comparing GM and BDG for
early diagnosis of invasive mould infections or candidaemia
included 82 adult patients with haematological malignancies.
Sensitivities of the BDG assay were consistently higher than
that of the GM EIA among all patient groups (47–64%), with
a speciﬁcity above 90% [56]. The lower performance of GM
detection may have been caused by concurrent antifungal
treatment. Interestingly, the GM assay revealed a signiﬁcantly
lower sensitivity for IA caused by Aspergillus fumigatus (13%)
than for non-fumigatus aspergillosis (49%), possibly reﬂecting
variable amounts of GM release among different Aspergillus
species.
There are currently inadequate data on the expression
of BDG and the diagnostic value of the BDG assays for IFIs
in paediatric patients. BDG detection may be a promising
tool for the diagnosis of invasive candidiasis in neonates
and in paediatric intensive-care patients [57]. Among the
IFIs that are especially distinctive in paediatric patients is
haematogenous Candida meningoencephalitis [58,59]. As this
infection is difﬁcult to diagnose and carries a high burden
of morbidity, CSF BDG may be a sensitive means of detec-
tion of this life-threatening and debilitating infection [60,61].
However, further validation of the BDG assays, including
the deﬁnition of cut-off values in children [62], requires fur-
ther study.
Mannan and anti-mannan antibodies
Like GM in moulds, circulating mannan, a characteristic cell
wall component of yeasts, has been evaluated as a diagnostic
marker for invasive candidiasis or candidaemia in adult patients
with neutropenia [63] and after haematopoietic stem cell
transplantion [64], with variable results. A preliminary study in
neonates has given promising results, particularly for exclusion
of candidiasis, considering the high NPV of 98% [65].
Detection of Fungal DNA
Molecular biology may provide powerful tools for the early
diagnosis of IFI. PCR has yielded the most promising data,
with high sensitivity and speciﬁcity. However, fungal PCR
differs from the molecular detection of other eukaryotic and
prokaryotic microorganisms with regard to several features:
low amounts and more complicated isolation of DNA
(particularly regarding the durable fungal cell wall), requiring
special extraction protocols; lack of standardized nucleic
acid detection procedures; and considerable susceptibility to
airborne and waterborne contamination, making the inter-
pretation of results difﬁcult.
Highly conserved DNA sequences within the multicopy
genes encoding 28S or 18S rRNA have been utilized as
‘panfungal’ primers, and primers spanning the 5.8S rRNA,
ITS-1 and ITS-2 regions have been used for the identiﬁcation
of speciﬁc fungal pathogens [66–68]. Sequences within the
28S rRNA region have been recently utilized for the
development of quantitative PCR assays for the detection of
Mucorales [69].
As with the biomarkers already discussed, twice-weekly
screening of high-risk patients [70–72] and rapid, speciﬁc
detection of fungal pathogens in tissue specimens [73] have
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emerged as the most feasible clinical applications of PCR in
IFI diagnosis to date. However, the fact that several millilitres
of whole blood are required per sample remains a quantita-
tive problem in small children. Although nested PCR is an
option for the detection of even small amounts of DNA
[74], it suffers from a higher probability of contamination.
However, the sensitivity and speciﬁcity were 80% and 81%,
respectively, when 291 blood, CSF or BAL samples from
71 paediatric and adolescent patients with two proven
and three probable IA cases were examined by means of
a nested PCR assay [75]. An earlier study using a panfungal
PCR assay in blood samples of paediatric cancer patients
with 28 cases of proven or probable IFI in 91 febrile
neutropenic episodes had yielded a sensitivity, speciﬁcity,
PPV and NPV of 75%, 92%, 84% and 87%, respectively [76].
Following classical, rather time-consuming approaches
[74,77], semi-automated DNA extraction [78] and real-time
PCR methods [46,79–81] have been developed, enabling the
rapid detection of a relevant array of fungal pathogens within
a few hours. In-house-developed PCR protocols with limited
availability and novel technologies such as ﬂuorescence in situ
hybridization have been studied [82,83] (Lass-Floerl et al.,
18th ECCMID, 2008, Poster P734) (Willinger B, personal
communication). However, further studies on standardization
and validation are needed [84].
Outlook
As bedside evaluation continues to be augmented by expand-
ing technologies of diagnostic imaging and novel systems for
detection of fungal growth, carbohydrates, proteins, lipids,
metabolites and nucleic acids, the capacity for diagnosis of
IFIs in children will continue to improve. Future studies con-
ducted in children are critical for understanding these infec-
tions in paediatric patients.
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